Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery

Neuropeptides

Volumn 34, Issue 5, 2000, Pages 272-280

  Hasenohrl R U ^a   Souza Silva, M A De ^a   Nikolaus, S ^b   Tomaz, C ^c   Brandao, M L ^d   Schwarting, R K W ^e   Huston, J P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Nuclear Medicine ^*  (Germany)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; ACETYLCHOLINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; OXIDOPAMINE; SUBSTANCE P;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CONTROLLED STUDY; LEARNING; MEMORY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0033753176     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1054/npep.2000.0824     Document Type: Article

References (52)

1. Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine
2. Tachykinins, neurotrophism and neurodegenerative diseases: A critical review on the possible role of tachykinins in the aetiology of CNS diseases
3. Acidic and basic fibroblast growth factors are present in and produce effects upon mesencephalic dopamine neurons
4. The C-terminal fragment of substance P enhances dopamine release in nucleus accumbens but not in neostriatum in freely moving rats
5. Effects of substance P on extracellular dopamine in neostriatum and nucleus accumbens
6. Substance P decreases extracellular concentrations of acetylcholine in neostriatum and nucleus accumbens in vivo: Possible relevance for the central processing of reward and aversion
7. Relationship between dopamine release in nucleus accumbens and place preference induced by substance P injected into the nucleus basalis magnocellularis region
8. Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions
9. In vivo neurochemical correlates of cognitive processes: Methodological and conceptual challenges
10. Aversive effects of the C-fragment of substance P in the dorsal periaqueductal gray matter
11. Anxiogenic effects of substance P and its 7-11 C terminal, but not the 1-7 N terminal, injected into the dorsal periaqueductal gray
12. Differential modulation of frontal cortex acetylcholine by injection of substance P into the nucleus basalis magnocellularis region in the freely-moving vs the anesthetized preparation
13. Anxiolytic action of a neurokinin 1 receptor antagonist in the social interaction test
14. Modulation of memory retention by neuropeptide K
15. Influence of substance P and fragments on passive avoidance behavior
16. Substance P (neurokinin-1) receptor mRNA is selectively expressed in cholinergic neurons in the striatum and basal forebrain
17. Functional anatomy of the ventral, limbic system-innervated striatum
18. Chronic administration of neurokinin SP improves maze performance in aged Rattus Norvegicus
19. Neuropeptide substance P improves water maze performance in aged rats
20. Anxiolytic-like action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region
21. Diversity in mammalian tachykinin peptidergic neurons: Multiple peptides, receptors, and regulatory mechanisms
22. The role of neuropeptides in learning: Focus on the neurokinin substance P
23. The relationship between reinforcement and memory: Parallels in the rewarding and mnemonic effects of the neuropeptide substance P
24. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P
25. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
26. On the physiological metabolism of substance P
27. Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1-11
28. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains
29. Interactions between the mu opioid agonist DAMGO and substance P in regulation of the ventral pallidum
30. Limbic-motor integration
31. Substance P in the ventral pallidum: Projection from the ventral striatum, and electrophysiological and behavioral consequences of pallidal substance P
32. Reinforcing effects of neurokinin substance P in the ventral pallidum: Mediation by the tachykinin NK1 receptor
33. The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection
34. Anxiolytic-like effects in rats produced by ventral pallidal injection of both N- and C-terminal fragments of substance P
35. Pretreatment with neurokinin substance P but not with cholecystokinin-8S can alleviate functional deficits of partial nigrostriatal 6-hydroxydopamine lesion
36. Pretreatment with fragments of substance P or with cholecystokinin differentially affects recovery from sub-total nigrostriata 6-hydroxydopamine lesion
37. Neurotransmitter functions of mammalian tachykinins
38. Ventral pallidum self-stimulation induces stimulus dependent increase in c-fos expression in reward-related brain regions
39. The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation
40. Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders
41. Short-term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the periaqueductal grey and limbic regions of rat brain
42. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists
43. Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN 51708
44. The tachykinin NK1 receptor in the brain: Pharmacology and putative functions
45. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments
46. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae
47. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat
48. Pharmacological characterization of tachykinin receptors controlling acetylcholine release from rat striatum: An in vivo microdialysis study
49. Genetic predisposition to high anxiety may be determined by a low level of substance P in the brain
50. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice
51. Brain substance P receptors in Parkinson's disease